Question 1

What was the main finding?

Accepted Answer

RUNX1 gene mutations are present in 26% of pediatric AML-M0 cases and directly cause resistance to standard chemotherapy, leading to a poorer prognosis.

Question 2

What other genetic changes were found?

Accepted Answer

The study found widespread DNA hypermethylation and frequent activating mutations in the RAS, FLT3, and JAK signaling pathways (83% of cases).

Question 3

What are the future treatment options?

Accepted Answer

Precision therapies like hypomethylating agents, signaling inhibitors, and metabolic targeting may be more effective than traditional chemotherapy for these patients.

Does the RUNX1 Mutation Cause Chemoresistance in Pediatric AML-M0?